Thank you to all of our speakers, sponsors and colleagues for making this event a great success!
Highlights from the Symposium…
We’ve reached the tipping point. The basic assumptions underlying product reimbursement are changing radically. And rapidly.
“The Evidence Challenge of Rational Reimbursement”
Presented by Roger Longman, CEO, Real Endpoints
One way for payers to get a handle on drug spending and simultaneously support real medical innovation is comparative efficacy – the transformational fuel for evidence-based prescribing and reimbursement. But self-interest, academic perfectionism, government and corporate priorities, political restrictions and accounting bureaucracy are all getting in the way of rational reimbursement decisions. The answer: knowing when to go with “good enough”.
Play complimentary recording here:
Download audio here: Audio
Download PDF slides here:Slides
Thought leaders
Lewis Sandy, MD
SVP, Clinical Advancement, UnitedHealth
Michael Sherman, MD
CMO, Harvard Pilgrim
Robert Galvin, MD
CEO, Equity Healthcare
Peter Bach, MD
Director of the Center for Health Policy & Outcomes, Memorial Sloan Kettering
Michael Kolodziej, MD
National Medical Director, Oncology Solutions, Office of the CMO, Aetna
Annalisa Jenkins, MD
EVP, Head of Global Development, Merck Serono
Jack Bailey
SVP, Policy, Payers & Vaccines, GlaxoSmithKline
Steve Wooding
VP, Head of Market Access, Janssen EMEA, J&J
Jay Galeota
President, Hospital and Specialty Care, Merck & Co. Inc.
…And more!
The Symposium provided specific recommendations on key issues such as…
- The new tech assessment and contracting opportunities opened up by bundled payments (and why traditional contracting can’t handle them);
- When, whether and how to use risk-sharing as a contracting strategy;
- Determining the adherence strategies payers & pharmas should use to create value;
- The kind and breadth real-world evidence you’ll actually need – and the data which is a waste of time;
- When treatment-linked diagnostics actually prove value to payers – and when they don’t;
- Developing or using the requisite comparative effectiveness data – and the clinical-trial endpoints necessary for optimal decision-making
Who Attended:
Payers and Risk-Sharing Providers
- CEO, CFO
- Medical Director
- Pharmacy Director
- Health Economics
- Technology Assessment
Biopharma/Med Device/Diagnostics
- CEO, CFO
- Senior Clinical Development
- Managed Markets
- Senior Marketing Executives
- Brand Management
- HEOR